Skip to main content
GIPResearch.com · Patent and Technology Research

GLIA, LLC GRANTED PATENT FOR COMPOSITIONS FOR THE TREATMENT OF DRY EYE SYNDROME.

Glia Inc. develops a digital customer service platform. The Company provides an artificial intelligence (AI) platform for financial services companies to communicate with customers using messaging, video, voice, and artificial intelligence. Glia serves customers worldwide. Glia Inc. filed a patent…

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for GLIA, LLC GRANTED PATENT FOR COMPOSITIONS FOR THE TREATMENT OF DRY EYE SYNDROME.
Research and original publication material

GLIA, LLC GRANTED PATENT FOR COMPOSITIONS FOR THE TREATMENT OF DRY EYE SYNDROME. — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

Glia Inc. develops a digital customer service platform. The Company provides an artificial intelligence (AI) platform for financial services companies to communicate with customers using messaging, video, voice, and artificial intelligence. Glia serves customers worldwide. Glia Inc. filed a patent application numbered 542/DELNP/2015 that is titled COMPOSITIONS FOR THE TREATMENT OF DRY EYE SYNDROME. The patent has been filed in the field of Pharmaceuticals. This Patent Application has been granted as Patent Number 352218. This invention relates to compositions and methods for treating eye disease and disorders. More importantly, the invention offers a composition containing progesterone and techniques of dealing with ocular surface ailments and disorders by applying these compositions topically. During the patent examination, the Patent Examiner raised objections under Section 3(d) of the Patents (Amended) Act, 2005 stating that certain Claims define a mere admixture resulting only in the aggregation of the properties of the components thereof. It is not clear if the combined agents act together to provide a technical effect that is greater than just the sum of the two or more agents alone, or whether the combination is, in fact, a mere juxtaposition with no interaction of the agents. Ratios of components are not disclosed in the principal claim. As a response, the Applicant submitted that the disputed claims were pending cancellation, thus, rendering the objection moot. Further, the Applicant also amended the remaining claims, which now illustrate a pharmaceutical composition. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to GLIA, LLC GRANTED PATENT FOR COMPOSITIONS FOR

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2020-12-07. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights